A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin®) in Healthy Chinese Males

• Main Authors: Jing Wu (Author), Guolan Wu (Author), Liangzhi Xie (Author), Duo Lv (Author), Chang Xu (Author), Huili Zhou (Author), Lihua Wu (Author), Jingjing Zhang (Author), Jianzhong Shentu (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2023-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background SCT510 is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), which is intended as a candidate biosimilar of bevacizumab that is approved for various metastatic cancers.Please confirm change in wording to match definition for VEGF belo...